Wetherby Asset Management Inc Inhibrx, Inc. Transaction History

Wetherby Asset Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$32.76 - $39.56 $173,791 - $209,865	-5,305 Reduced 3.89%	131,023 $4.58 Million
Q3 2023 Nov 14, 2023	SELL	$15.75 - $26.31 $1,496 - $2,499	-95 Reduced 0.07%	136,328 $2.5 Million
Q1 2023 May 12, 2023	BUY	$18.45 - $27.14 $1,752 - $2,578	95 Added 0.07%	136,423 $2.57 Million
Q4 2022 Feb 14, 2023	SELL	$20.18 - $33.33 $20,180 - $33,330	-1,000 Reduced 0.73%	136,328 $3.36 Million
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $894 - $2,652	105 Added 0.08%	137,328 $1.56 Million
Q2 2021 Aug 16, 2021	BUY	$14.69 - $27.52 $2.02 Million - $3.78 Million	137,223 New	137,223 $3.78 Million

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Wetherby Asset Management Inc with notifications on news.